Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Grape Seed Extract Increases Effectiveness of Chemotherapy While Alleviating Damaging Side Effects

By LabMedica International staff writers
Posted on 25 Feb 2014
Australian cancer researchers have shown that grape seed extract can alleviate some of the damage caused by chemotherapy for colon cancer while increasing the effectiveness of the treatment.

Grape seed extract is used as a folk or traditional remedy for conditions related to the heart and blood vessels, such as atherosclerosis, high blood pressure, high cholesterol, and poor circulation; complications related to diabetes, such as nerve and eye damage; vision problems, such as macular degeneration; swelling after an injury or surgery; cancer prevention; and wound healing. More...
Previous work with cancer cells found that compounds in grape seed extract created an environment that was unfavorable for cancer cell growth.

Investigators at the University of Adelaide (Australia) worked with commercially available grape seed extract that was composed of tannins extracted from the grape seeds that had been freeze-dried and powdered. The extract was tested in laboratory studies using colon cancer cells grown in culture and in a rat cancer model.

Results published in the January 21, 2014, online edition of the journal PLOS ONE revealed that the grape seed extract increased the growth-inhibitory effects of chemotherapy (5-Fluorouracil) on colon cancer cells in culture by 26%. In the animal model the extract showed no side effects on healthy intestinal tissue at concentrations of up to 1,000 milligrams per kilogram. Co-treatment with the extract decreased chemotherapy-induced inflammation by up to 55% and significantly decreased intestinal damage compared to the chemotherapy control.

"This is the first study showing that grape seed can enhance the potency of one of the major chemotherapy drugs in its action against colon cancer cells," said first author Dr. Amy Cheah, a researcher at the University of Adelaide. "Our research also showed that in laboratory studies grape seed taken orally significantly reduced inflammation and tissue damage caused by chemotherapy in the small intestine, and had no harmful effects on noncancerous cells. Unlike chemotherapy, grape seed appears to selectively act on cancer cells and leave healthy cells almost unaffected."

"Our experimental studies have shown that grape seed extract reduced chemotherapy-induced inflammation and damage and helped protect healthy cells in the gastrointestinal tract," said Dr. Cheah. "While this effect is very promising, we were initially concerned that grape seed could reduce the effectiveness of the chemotherapy. In contrast, we found that grape seed extract not only aided the ability of chemotherapy to kill cancer cells, but was also more potent than the chemotherapy we tested at one concentration."

Related Links:

University of Adelaide



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: iStock

AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health

Advances in molecular diagnostics are creating new opportunities to improve the detection of sexually transmitted infections, identify antibiotic resistance, and assess cancer recurrence risk in women.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.